Superficial bladder carcinoma treated with bacillus Calmette-Guerin: Progression-free and disease specific survival with minimum 10-year followup

Journal of Urology

Volumn 167, Issue 2 I, 2002, Pages 494-501

  Davis, John W ^a   Sheth, Seemit I ^a   Doviak, Michael J ^a   Schellhammer, Paul F ^a  

^a OLD DOMINION UNIVERSITY   (United States)

Author keywords

Bladder neoplasms; Cystectomy; Mycobacterium bovis; Recurrence; Survival

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0036144868     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-200202000-00011     Document Type: Article

References (19)

1. Cancer statistics, 2001
2. Urothelial tumors of the urinary tract
3. Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder
4. Bacullus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer
5. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG
6. Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder
7. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma
8. Recurrence and progression in low grade papillary urothelial tumors
9. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer
10. The relationship among multiple recurrences, progression, and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years
11. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer
12. Intravesical bacillus Calmette-Guerin therapy prevents progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial
13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study
14. The treated natural history of high risk superficial bladder cancer: 15-Year outcome
15. Tumor progression and survival of patients with high grade, noninvasive papillary (TAG3) bladder tumors: 15-Year outcome
16. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer
17. Radical cystectomy - Often too late?
18. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction
19. Second resection and prognosis of primary high risk superficial bladder cancer: Is cystectomy often too early?